In a report released today, Robert LeBoyer from Noble Financial reiterated a Buy rating on MAIA Biotechnology, Inc. (MAIA – Research Report), ...

Maia Biotechnology Inc’s profitability metrics reveal financial health. The company currently boasts a gross margin of -32.20%. The profit margin, also known as the revenue ratio or gross profit ratio ...

MAIA Biotechnology (MAIA) announced updated data from its THIO-101 pivotal Phase 2 clinical trial evaluating its lead clinical candidate, THIO, ...

MAIA首席执行官Vlad ...

CHICAGO - MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical-stage biopharmaceutical company with a market capitalization of $49.4 million, has announced updated data from its Phase 2 clinical ...

MAIA Biotechnology, Inc., ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced positive updated data from its THIO-101 ...

After hours: February 3 at 5:16:04 PM EST Loading Chart for MAIA ...

芝加哥 - 市值5200万美元的临床阶段生物制药公司MAIA Biotechnology, Inc. (NYSE American: MAIA)宣布与百济神州合作,开展评估其端粒靶向药物THIO与检查点抑制剂替雷利珠单抗联合用药的2期临床试验。这些试验将针对肝细胞癌(HCC)、小细胞肺癌(SCLC)和结直肠癌(CRC)。根据InvestingPro的数据,分析师给出的MAIA股票目标价区间为11.

CHICAGO, January 10, 2025--(BUSINESS WIRE)--MAIA Biotechnology, Inc., (NYSE American: MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company ...

A treatment for patients living with advanced non-small cell lung cancer (NSCLC) who failed two or more standard-of-care (SOC ...